AU2022345881A1 — Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
Assigned to Alnylam Pharmaceuticals Inc · Expires 2024-03-21 · 2y expired
What this patent protects
The present invention relates to modulators, e.g., double stranded RNA (dsRNA) agents, antisense polynucleotide agents, antibodies, guideRNAs that effect ADAR editing, or guideRNAs that effect CRISPR editing, that modulate, e.g., inhibit, the expression and/or activity of inhibin…
USPTO Abstract
The present invention relates to modulators, e.g., double stranded RNA (dsRNA) agents, antisense polynucleotide agents, antibodies, guideRNAs that effect ADAR editing, or guideRNAs that effect CRISPR editing, that modulate, e.g., inhibit, the expression and/or activity of inhibin subunit beta E (INHBE). The invention also relates to methods of using such modulators to inhibit expression and/or activity of INHBE and to methods of preventing and treating an INHBE- associated disorder, e.g., metabolic disorder, e.g., metabolic syndrome, in a subject.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.